Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection
- PMID: 15564745
- DOI: 10.1159/000080877
Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection
Abstract
Objective: During the course of chronic hepatitis B virus (HBV) infection, severe acute exacerbations of the infection often occur spontaneously and follow a fulminating progression to fatal hepatic failure. The aim of this study was to clarify potential factors, including benefit of lamivudine therapy, which could influence clinical course of the serious disease in an area of intermediate HBV endemicity.
Methods and results: Using a database of 3,163 chronically HBV-infected patients, 418 (13.2%) developed acute exacerbation of hepatitis B. Of the 418 patients, 52 (12.4%) spontaneously developed severe acute exacerbation and were included in this study. Of the 52 patients, 23 were treated with lamivudine. In multivariate analyses, fulminating progression to hepatic failure (odds ratio, 15.45; 95% confidence interval, 3.71-64.41; p = 0.0002) was a significantly independent predictor of patient survival. Three variables were independently associated with fulminating development of hepatic failure: presence of cirrhosis (29.06, 1.74-85.56, 0.019, respectively), higher baseline bilirubin level (14.89, 1.31-52.91, 0.029, respectively), and genotype B (22.14, 1.59-29.68, 0.021, respectively). Treatment lacking lamivudine was a significant factor that contributed to shorter survival time, development of hepatic failure, and progression to cirrhosis in univariate analyses (p = 0.014, 0.012 and 0.0030, respectively).
Conclusion: In an area of intermediate HBV endemicity, certain proportion of chronic hepatitis B patients could spontaneously develop the serious disease. Factors influencing clinical course of the disease should be identified to improve prognosis and establish more rational and effective therapeutic strategies. Lamivudine therapy could potentially benefit the serious disease, although larger series of patients and longer follow-up periods are needed.
2004 S. Karger AG, Basel.
Similar articles
-
Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study.Am J Gastroenterol. 2001 Feb;96(2):557-62. doi: 10.1111/j.1572-0241.2001.03559.x. Am J Gastroenterol. 2001. PMID: 11232706
-
Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.Antivir Ther. 2008;13(4):571-9. Antivir Ther. 2008. PMID: 18672536 Clinical Trial.
-
Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.J Gastroenterol Hepatol. 2010 Mar;25(3):583-90. doi: 10.1111/j.1440-1746.2009.06089.x. Epub 2009 Nov 24. J Gastroenterol Hepatol. 2010. PMID: 19968744
-
[Clinical outcome in cases of viral breakthrough during lamivudine therapy in chronic hepatitis B patients].Taehan Kan Hakhoe Chi. 2002 Dec;8(4):389-96. Taehan Kan Hakhoe Chi. 2002. PMID: 12506243 Korean.
-
Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.J Gastroenterol Hepatol. 2005 Mar;20(3):426-32. doi: 10.1111/j.1440-1746.2004.03534.x. J Gastroenterol Hepatol. 2005. PMID: 15740488
Cited by
-
On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study.BMC Res Notes. 2013 Sep 2;6:349. doi: 10.1186/1756-0500-6-349. BMC Res Notes. 2013. PMID: 24004574 Free PMC article.
-
The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure.Hepatol Int. 2016 May;10(3):462-9. doi: 10.1007/s12072-015-9667-4. Epub 2015 Oct 19. Hepatol Int. 2016. PMID: 26482576 Clinical Trial.
-
Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure.Hepatol Int. 2015 Jul;9(3):373-7. doi: 10.1007/s12072-014-9569-x. Epub 2014 Sep 21. Hepatol Int. 2015. PMID: 25788180 Review.
-
Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.J Gastroenterol. 2012 Sep;47(9):1022-9. doi: 10.1007/s00535-012-0561-8. Epub 2012 Feb 29. J Gastroenterol. 2012. PMID: 22370817
-
Entecavir and lamivudine therapy for severe acute chronic hepatitis B.Exp Ther Med. 2013 Feb;5(2):545-548. doi: 10.3892/etm.2012.850. Epub 2012 Dec 5. Exp Ther Med. 2013. PMID: 23403957 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources